TY - JOUR
T1 - Prognostic significance of DNA ploidy in Ta/Tl bladder cancer
T2 - A southwest oncology group study
AU - DeVere White, Ralph W.
AU - Deitch, Arline D.
AU - Tesluk, Henry
AU - Blumenstein, Brent
AU - Lowe, Bruce A.
AU - Sagalowsky, Arthur I
AU - Smith, Joseph A.
AU - Schellhammer, Paul F.
AU - Stanisic, Thomas H.
AU - Grossman, H. Barton
AU - Messing, Edward
AU - Crissman, John D.
AU - Crawford, E. David
N1 - Funding Information:
This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute. DHHS: CA46113, CA22433. CA13612, CA42777, CA46441, CA46282, CA13238, CA45560, CA20319, CA27057, CA16385, CA28862, CA35192. CA35431, CA12213. CA22411, CA35090, CA32734, CA35178, CA35281, CA14028, CA35261. CA35117, CA45450, CA52420, CA37981, CA04919, CA36020, CA38926. CA32102, CA49957, CA21076, CA49957, CA21076.
PY - 1996
Y1 - 1996
N2 - While 80% of transitional cell carcinomas (TCC) present as Ta/Tl lesions, they account for only 15% of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with Ta/Tl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage Tl tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.
AB - While 80% of transitional cell carcinomas (TCC) present as Ta/Tl lesions, they account for only 15% of deaths caused by TCC. We have evaluated the ability of DNA ploidy analysis to predict outcome in 228 patients with Ta/Tl TCC. All patients were judged to be at increased risk for tumor recurrence due to having two occurrences of Stage Tl tumor within 56 weeks, or three or more tumors presenting simultaneously within 16 weeks of registration. Concurrent carcinoma in situ was acceptable. All patients were treated with either bacillus Calmette Guerin (BCG) immunotherapy or mitomycin-C (MMC) intravesical chemotherapy. Patients with nondiploid tumors had higher hazard rates for both tumor progression and death (p = 0.007 and p = 0.016, respectively); however, the prognostic information of DNA ploidy was not additive to tumor grade.
UR - http://www.scopus.com/inward/record.url?scp=0029785951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029785951&partnerID=8YFLogxK
U2 - 10.1016/1078-1439(96)00031-2
DO - 10.1016/1078-1439(96)00031-2
M3 - Article
C2 - 21224132
AN - SCOPUS:0029785951
SN - 1078-1439
VL - 2
SP - 27
EP - 34
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 1
ER -